- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03340727
Moderately Preterm Infants With Caffeine at Home for Apnea (MoCHA) Trial (MoCHA)
Randomized Controlled Trial of Home Therapy With Caffeine Citrate in Moderately Preterm Infants With Apnea of Prematurity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study subjects will be patients in the NICU at one of the participating hospitals at a Neonatal Research Network site. Infants who meet the eligibility criteria will be randomized to either caffeine citrate at 10 mg/kg/dose or placebo (equal volume of all the excipients except for the active ingredient, caffeine citrate) to be given daily beginning within 72 hours of open label caffeine discontinuation. The infant may still require hospitalization for observation after discontinuation of open label caffeine or for other discharge issues such as temperature control or feeding tolerance.
Once deemed ready for discharge, infants will be continued at home on the same dose of caffeine citrate or placebo for the first 28 days after hospital discharge. On the day of discharge, the parent will be supplied with 28 numbered vials with oral caffeine citrate (intervention group) or placebo at an equivalent volume (placebo group).
The parents will be educated by the research nurse, discharge nurse, physician, or pharmacist on storage and administration of study medication. A member of the research team will contact the parents to obtain post-discharge information within 72 hours after discharge, once a week for the first 4 weeks, and biweekly during the weeks 5 to 8 after discharge.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Waldemar Carlo, MD
- Phone Number: 205-934-4680
- Email: wcarlo@peds.uab.edu
Study Contact Backup
- Name: Abhik Das, PhD
- Phone Number: 301-230-4640
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham
-
-
California
-
Palo Alto, California, United States, 94304
- Stanford University
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- Emory University
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- University of New Mexico
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University
-
Durham, North Carolina, United States, 27705
- RTI International
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Cincinnati Children's Medical Center
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve University, Rainbow Babies and Children's Hospital
-
Columbus, Ohio, United States, 43205
- Research Institute at Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02905
- Brown University, Women & Infants Hospital of Rhode Island
-
-
Texas
-
Dallas, Texas, United States, 75235
- University of Texas Southwestern Medical Center at Dallas
-
Houston, Texas, United States, 77030
- University of Texas Health Science Center at Houston
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Inborn and outborn infants of 29 0/7 to 33 6/7 weeks gestational age at birth
- admitted to hospitals of the NICHD NRN who, are at time of enrollment:
- ≤35 6/7 weeks post-menstrual age at the time of randomization
- Receiving caffeine with plan to discontinue treatment or just discontinued caffeine treatment
- Receiving feeds at a volume of ≥120 ml/kg/day by oral and/or tube feeding
- Ability to start study medication within 72 hours after stopping caffeine
Exclusion Criteria:
- On respiratory therapy (oxygen more than room air equivalent for high altitude sites, nasal cannula, continuous positive pressure ventilation, and/or mechanical ventilation)
- Infants who would otherwise be discharged home on apnea monitor due to underlying disease or family history, including history of a sibling with sudden infant death syndrome
- Parental request for apnea monitor
- Congenital heart disease other than atrial septal defect, ventricular septal defect, or patent ductus arteriosus
- Neuromuscular conditions affecting respiration
- Major congenital malformation and/or genetic disorder
- Plans to transfer to a non-NRN site before discharge
- Unable to obtain parental or guardian consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Caffeine Citrate
Caffeine citrate at 10 mg/kg/dose (5 mg/kg caffeine base) daily, in hospital.
Infants will continue at home on the same dose of caffeine citrate for the first 28 days after hospital discharge.
|
The study intervention is caffeine citrate given once daily at 10 mg/kg/day.
It is given orally, before hospital discharge and 28 days after discharge.
|
PLACEBO_COMPARATOR: Placebo
Placebo contains all of the excipients except for the active ingredient, caffeine citrate, (a volume equivalent to 10 mg/kg of caffeine citrate) and given daily.
Infants will be continued at home on the same dose of placebo for the first 28 days after hospital discharge.
|
The study intervention is placebo given once daily at a volume equivalent to 10 mg/kg of caffeine citrate.
It is given orally, before hospital discharge and 28 days after discharge.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of days of hospitalization
Time Frame: Randomization until discharge up to 48 wks PMA
|
The number of days of hospitalization from randomization to discharge up to 48 weeks postmentrual age (PMA), with censoring at time of transfer or death.
|
Randomization until discharge up to 48 wks PMA
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of days to physiologic maturity after randomization
Time Frame: Randomization until physiologic maturity up to 48 wks PMA
|
Physiologic maturity is defined as: 1) Temperature: out of the incubator for at least 48 hours with normal body temperature, 2) Feeding: oral feeding at a volume of at least 140 ml/kg/day or growing on less than 140 ml/kg/day for at least 48 hours and 3) Respiratory: apnea-free for at least 5 days.
The number of days to physiologic maturity after randomization up to 48 wks PMA, with censoring at time of transfer or death.
|
Randomization until physiologic maturity up to 48 wks PMA
|
PMA at discharge
Time Frame: Randomization until discharge up to 48 wks PMA
|
Post menstrual age at discharge up to 48 wks PMA, censoring at time of transfer or death.
|
Randomization until discharge up to 48 wks PMA
|
The number of all-cause hospital re-admissions
Time Frame: Discharge until eight weeks after discharge up to 52 wks PMA
|
The number of all-cause re-admissions to the hospital within the first four weeks, second four weeks, and first eight weeks combined among those discharged from the hospital by 48 wks PMA.
|
Discharge until eight weeks after discharge up to 52 wks PMA
|
The number of all-cause sick visits
Time Frame: Discharge until eight weeks after discharge up to 52 wks PMA
|
The number of all-cause sick visits to urgent care, emergency rooms, or health care provider's office within the first four weeks, second four weeks, and first eight weeks combined among those discharged from the hospital by 48 wks PMA.
|
Discharge until eight weeks after discharge up to 52 wks PMA
|
Death
Time Frame: Randomization until eight weeks after discharge up to 52 wks PMA
|
All cause mortalities
|
Randomization until eight weeks after discharge up to 52 wks PMA
|
Weight
Time Frame: Randomization until discharge up to 48 wks PMA
|
Weight will be recorded at time of of birth, randomization and at status: discharge up to 48 wks PMA ,with censoring at time of transfer or death
|
Randomization until discharge up to 48 wks PMA
|
Elevated Heart Rate
Time Frame: Randomization until discharge up to 48 wks PMA
|
The number of days after randomization that infant had at least two consecutive heart rates >200 documented at least 3 hours apart (when infant not crying) until discharge up to 48 wks PMA, with censoring at time of transfer or death
|
Randomization until discharge up to 48 wks PMA
|
High Blood Pressure
Time Frame: Randomization until discharge up to 48 wks PMA
|
Treatment for high blood pressure initiated after randomization until discharge up to 48 wks PMA, with censoring at time of transfer or death
|
Randomization until discharge up to 48 wks PMA
|
Periods of NPO
Time Frame: Randomization until discharge up to 48 wks PMA
|
The number of episodes between randomization and status (discharge up to 48 wks PMA, with censoring at time of transfer or death) that infant was placed NPO for ≥ 24 hours.
|
Randomization until discharge up to 48 wks PMA
|
Reflux
Time Frame: Randomization until discharge up to 48 wks PMA
|
The use of anti-reflux medications started between randomization and status (discharge up to 48 wks PMA, with censoring at time of transfer or death)
|
Randomization until discharge up to 48 wks PMA
|
Significant Apnea
Time Frame: Randomization until discharge up to 48 wks PMA
|
The number of days that significant apnea, as defined by receiving open label caffeine, CPAP for apnea or ventilatory support for apnea, is documented between randomization and status (discharge up to 48 wks PMA, with censoring at time of transfer or death)
|
Randomization until discharge up to 48 wks PMA
|
Significant Bradycardia
Time Frame: Randomization until discharge up to 48 wks PMA
|
The number of days that significant bradycardia, as defined by receiving treatment, is documented between randomization and status (discharge up to 48 wks PMA, with censoring at time of transfer or death)
|
Randomization until discharge up to 48 wks PMA
|
Arrhythmia
Time Frame: Randomization until discharge up to 48 wks PMA
|
The presence of documented and treated arrhythmias between randomization and status (discharge up to 48 wks PMA, with censoring at time of transfer or death), not due to tachycardia or bradycardia
|
Randomization until discharge up to 48 wks PMA
|
Seizures
Time Frame: Randomization until discharge up to 48 wks PMA
|
The onset of documented seizures, as defined by treating with anti-convulsants, between randomization and status (discharge up to 48 wks PMA, with censoring at time of transfer or death).
|
Randomization until discharge up to 48 wks PMA
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Respiration Disorders
- Signs and Symptoms, Respiratory
- Pregnancy Complications
- Obstetric Labor Complications
- Obstetric Labor, Premature
- Apnea
- Premature Birth
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Purinergic Antagonists
- Purinergic Agents
- Phosphodiesterase Inhibitors
- Purinergic P1 Receptor Antagonists
- Central Nervous System Stimulants
- Caffeine
- Caffeine citrate
Other Study ID Numbers
- NICHD-NRN-0056
- UG1HD034216 (U.S. NIH Grant/Contract)
- UG1HD027904 (U.S. NIH Grant/Contract)
- UG1HD021364 (U.S. NIH Grant/Contract)
- UG1HD027853 (U.S. NIH Grant/Contract)
- UG1HD040689 (U.S. NIH Grant/Contract)
- UG1HD040492 (U.S. NIH Grant/Contract)
- UG1HD027851 (U.S. NIH Grant/Contract)
- UG1HD087229 (U.S. NIH Grant/Contract)
- UG1HD053109 (U.S. NIH Grant/Contract)
- UG1HD068278 (U.S. NIH Grant/Contract)
- UG1HD068244 (U.S. NIH Grant/Contract)
- UG1HD068263 (U.S. NIH Grant/Contract)
- UG1HD027880 (U.S. NIH Grant/Contract)
- UG1HD053089 (U.S. NIH Grant/Contract)
- UG1HD087226 (U.S. NIH Grant/Contract)
- U10HD036790 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Apnea of Prematurity
-
University of ManitobaCanadian Institutes of Health Research (CIHR); The Children's Hospital Foundation...Completed
-
Children's Hospital of Fudan UniversityCompletedApnea of Prematurity
-
NobelpharmaCompleted
-
Daping Hospital and the Research Institute of Surgery...Unknown
-
Mednax Center for Research, Education, Quality...CompletedApnea of PrematurityUnited States
-
University of MiamiThe Gerber FoundationCompletedApnea of Prematurity | Periodic Breathing | Desaturation of Blood | Central Apnea | Obstructive Apnea of NewbornUnited States
-
Wyss Institute at Harvard UniversityBeth Israel Deaconess Medical Center; University of Massachusetts, WorcesterCompletedApnea of PrematurityUnited States
-
Ain Shams UniversityUnknown
-
McMaster UniversityNational Health and Medical Research Council, Australia; Canadian Institutes...CompletedApnea of PrematurityCanada, United States, Israel, Australia, Netherlands, United Kingdom, Switzerland, Germany, Sweden
-
University of ManitobaManitoba Institute of Child HealthTerminatedApnea of PrematurityCanada
Clinical Trials on Caffeine Citrate
-
Mansoura University Children HospitalCompleted
-
University of North Carolina, Chapel HillThrasher Research FundActive, not recruiting
-
Sharp HealthCareCompletedCaffeineUnited States
-
Duke UniversityUniversity of North Carolina, Chapel HillCompletedApnea of Prematurity | Caffeine | Premature NewbornUnited States
-
University of FlorenceCompleted
-
Ain Shams UniversityCompleted
-
Hadassah Medical OrganizationCompleted
-
Ain Shams UniversityUnknown
-
McMaster UniversityNational Heart, Lung, and Blood Institute (NHLBI); Canadian Institutes of Health...CompletedApnea of PrematurityAustralia, Canada
-
Seoul St. Mary's HospitalCompletedApnea of Prematurity | Caffeine | PretermKorea, Republic of